Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)

  • Technology appraisal
  • TA762
  • Published: 

History

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators